Stocktoria

Pulmatrix, Inc. PULM

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-03-21 · LEI

Pulmatrix, Inc. financials (annual)

Revenue
$835000 $335000 $153000 $7.9M $12.6M $5.2M $6.1M $7.3M $7.8M 2016201720182019202020212022202320242025
Net income
-$27.8M -$18.1M -$20.6M -$20.6M -$19.3M -$20.2M -$18.8M -$14.1M -$9.6M -$5.2M 2016201720182019202020212022202320242025
Free cash flow
-$13.7M -$14.6M -$16.8M $3.2M -$12.8M -$19.9M -$19.4M -$16.7M -$11.1M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$7.8M$7.3M$6.1M$5.2M$12.6M$7.9M$153,000$335,000$835,000
R&D expense$38,000$7.2M$15.5M$18.2M$15.4M$15.6M$12.8M$13.0M$10.2M$10.2M
Operating income-$5.2M-$9.8M-$14.7M-$18.9M-$20.2M-$9.9M-$20.7M-$20.4M-$17.5M-$24.9M
Interest expense$186,000$643,000$881,000
Income tax$0-$3.0M
Net income-$5.2M-$9.6M-$14.1M-$18.8M-$20.2M-$19.3M-$20.6M-$20.6M-$18.1M-$27.8M
EPS (diluted)$-1.41$-2.62$-3.87$-5.46
Operating cash flow-$5.4M-$10.7M-$16.0M-$19.4M-$19.7M-$12.5M$3.2M-$16.8M-$14.5M-$13.2M
Free cash flow-$11.1M-$16.7M-$19.4M-$19.9M-$12.8M$3.2M-$16.8M-$14.6M-$13.7M
Cash & equivalents$4.1M$9.5M$19.2M$35.6M$53.8M$31.7M$23.4M$2.6M$3.5M$4.2M
Total assets$4.1M$9.9M$34.0M$41.0M$58.8M$38.1M$36.1M$14.7M$16.0M$16.7M
Total liabilities$329,000$996,000$16.0M$9.8M$11.4M$15.0M$25.1M$2.9M$5.8M$7.9M
Shareholders' equity$3.8M$8.9M$18.0M$31.1M$47.4M$23.1M$11.0M$11.8M$10.1M$8.8M

Growth · year-over-year · Revenue CAGR 32.2%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+7.0%+20.2%+17.5%-59.1%+59.7%+5069.9%-54.3%-59.9%-30.5%
Free cash flow growth-502.4%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.